Accenture’s study of the biopharmaceutical industry is in its 11th year and has analyzed the long-term performance of “pure-play” pharmaceutical companies (those with more than 75 percent of their revenue derived from pharmaceutical products).
Our 2016 update is based on trailing 12-month Q3 2015 financials and analyzes 16 of the largest pure-play pharmaceutical companies in the world over an eight-year period. Collectively these companies had $423 billion in aggregate global revenue, representing nearly half the global pharmaceutical market by net sales. The results have been compared with our 2015 and 2014 studies to identify relative movements in the performance rankings. The analysis pro forma adjusts for the impact of major M&A deals (but not smaller bolt-on deals) and removes the impact of exceptional costs to reveal a normalized picture of ongoing core business operations.
A detailed analysis of historic financial performance averaged over one, three, five and seven-year timeframes is combined with consensus analyst forecasts to gain a forward-looking global picture of forecasted revenue growth from portfolio and new product launches as well as to gauge the impact of patent expirations and mature products.